RA PHARMACEUTICALS INC's ticker is RARX and the CUSIP is 74933V108. A total of 65 filers reported holding RA PHARMACEUTICALS INC in Q2 2017. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2020 | $24,673,000 | -50.0% | 513,937 | -51.1% | 0.01% | +20.0% |
| Q4 2019 | $49,330,000 | +304.7% | 1,051,168 | +104.0% | 0.01% | +66.7% |
| Q3 2019 | $12,188,000 | -9.3% | 515,377 | +15.3% | 0.00% | 0.0% |
| Q2 2019 | $13,440,000 | +61.5% | 446,988 | +20.3% | 0.00% | +50.0% |
| Q1 2019 | $8,321,000 | -25.7% | 371,488 | -39.6% | 0.00% | 0.0% |
| Q4 2018 | $11,192,000 | +236.3% | 615,028 | +234.3% | 0.00% | +100.0% |
| Q3 2018 | $3,328,000 | +130.0% | 183,975 | +26.5% | 0.00% | – |
| Q2 2018 | $1,447,000 | +139.2% | 145,465 | +27.6% | 0.00% | – |
| Q1 2018 | $605,000 | -15.4% | 114,037 | +35.4% | 0.00% | – |
| Q4 2017 | $715,000 | -36.2% | 84,219 | +9.7% | 0.00% | – |
| Q3 2017 | $1,121,000 | -20.4% | 76,784 | +2.2% | 0.00% | -100.0% |
| Q2 2017 | $1,408,000 | -6.6% | 75,137 | +6.0% | 0.00% | 0.0% |
| Q1 2017 | $1,508,000 | +52.0% | 70,863 | +8.5% | 0.00% | – |
| Q4 2016 | $992,000 | – | 65,341 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RA Capital Management | 3,851,808 | $20,453,000 | 1.57% |
| NEA Management Company, LLC | 5,493,636 | $29,171,000 | 1.30% |
| Foresite Capital Management IV, LLC | 450,000 | $2,390,000 | 0.99% |
| Novo Holdings A/S | 1,465,838 | $7,784,000 | 0.98% |
| Consonance Capital Management LP | 1,454,761 | $7,725,000 | 0.71% |
| VHCP Management II, LLC | 544,612 | $2,892,000 | 0.70% |
| ACUTA CAPITAL PARTNERS, LLC | 270,000 | $1,434,000 | 0.23% |
| Athanor Capital, LP | 67,150 | $357,000 | 0.16% |
| Rock Springs Capital Management LP | 600,000 | $3,186,000 | 0.14% |
| Eventide Asset Management | 388,000 | $2,060,000 | 0.10% |